Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.42 | 0.69 | -38.93 |
| EPS, GAAP | 0.30 | 0.49 | 0.49 |
| Consensus Estimate | 0.81 | 0.95 | -15.13 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 2.49 | 2.61 | -4.61 |
| EPS, GAAP | 2.00 | 2.02 | -0.89 |
| Consensus Estimate | 3.80 | 3.76 | 1.06 |
| MRK | Industry Average | |
| P/E (TTM) | 22.23 | NA |
| P/E (Forward) | 12.47 | NA |
| PEG Ratio | 3.32 | 2.20 |
| Price/Sales | 2.90 | 18.91 |
| Beta | 0.77 | 0.70 |
| 11:55 AM | 4/3/2013 | Merck Unit, Sun Pharma File Patent Suit Against Glenmark |
| 10:20 AM | 3/20/2013 | Model N Shares Rise After IPO |
| 4/5/2013 | 'Guided Missiles' to Treat Cancer (WSJ.com) |
| 4/2/2013 | Options Traders Position for Health-Care Pullback (WSJ.com) |
| 3/27/2013 | Merrill Lynch Picks Diabetes Drug Makers as Real Winners (MRK, BMY, LLY, NOV, MNKD, BAC) (24/7 Wall St) |
| 3/27/2013 | Short Sellers Increase Their Bets Against Top Dividend Stocks (MO, AEP, NLY, T, DUK, GE, KMB, KMP, MRK, PG, RAI, VZ) (24/7 Wall St) |
| 3/16/2013 | Zoetis: Too Many Folks' Pet Stock (Barrons.com) |
| 3/14/2013 | FDA Opens Safety Review of Diabetes Drugs (WSJ.com) |
| 3/14/2013 | Here's What a Fidelity ETF Might Look Like (Barrons.com) |
| 3/12/2013 | Panel Clears Merck's Vytorin Trial to Continue (WSJ.com) |
